INSIGHTEC is the global leader in the technology of MR-guided-Focused Ultrasound (MRgFUS). The company develops and distributes an MRgFUS therapy platform, Exablate, that is transforming medicine by providing a non-invasive therapeutic alternative to millions of potential patients around the world.
INSIGHTEC's Exablate platform is used to treat a variety of indications in Women’s Health, Oncology and Neurosurgery. MRgFUS technology was developed over a decade ago and it has been proven safe and effective through numerous clinical trials. The Exablate system has received CE for treating symptomatic uterine fibroids and adenomyosis, pain palliation of bone metastases, osteoid osteoma, facet joints arthritis, malignant and benign local bone tumour control, Essential Tremor, Tremor Dominant Parkinson's Disease and Neuropathic Pain. The technology has been embraced by leading physicians around the world.
For more information on INSIGHTEC'S applications, visit: www.essential-tremor.c
om | www.insightec.com